Paper42014656
The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.
Mirzaee F and 3 others. Ann Hematol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications. Papers, record 42014656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42014656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia, Sickle Cell | Major topic |
| Hydroxyurea | Major topic |
| MicroRNAs | Major topic |
| Gene Expression Regulation | Major topic |
| Antisickling Agents | Major topic |
| Humans | |
| Animals |
Source PubMed
References80
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38188295 | The microRNA target site profile is a novel biomarker in the immunotherapy response. | Front Oncol | 2023 | https://conductscience.org/library/papers/38188295 | PubMed |
| 2 | 40087738 | Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases. | BMC Med Ethics | 2025 | https://conductscience.org/library/papers/40087738 | PubMed |
| 3 | 40589088 | Transferrin Purification, Biophysical Characterization, and Lung Biodistribution in Sickle Cell Disease Mice. | Biotechnol Bioeng | 2025 | https://conductscience.org/library/papers/40589088 | PubMed |
| 4 | 33807258 | Distinct miRNA Signatures and Networks Discern Fetal from Adult Erythroid Differentiation and Primary from Immortalized Erythroid Cells. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33807258 | PubMed |
| 5 | 28696844 | Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea. | Hemoglobin | 2017 | https://conductscience.org/library/papers/28696844 | PubMed |
| 6 | 36677692 | Recent Advances on Small-Molecule Antagonists Targeting TLR7. | Molecules | 2023 | https://conductscience.org/library/papers/36677692 | PubMed |
| 7 | 39512697 | Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155. | Int J Med Sci | 2024 | https://conductscience.org/library/papers/39512697 | PubMed |
| 8 | 35080707 | Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. | Pharm Res | 2022 | https://conductscience.org/library/papers/35080707 | PubMed |
| 9 | 36815490 | The future of sickle cell disease therapeutics rests in genomics. | Dis Model Mech | 2023 | https://conductscience.org/library/papers/36815490 | PubMed |
| 10 | 40187617 | MicroRNAs in sickle cell disease: A comprehensive review. | Gene | 2025 | https://conductscience.org/library/papers/40187617 | PubMed |
| 11 | 21921042 | Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. | Blood | 2011 | https://conductscience.org/library/papers/21921042 | PubMed |
| 12 | 34247076 | Global research on the air quality status in response to the electrification of vehicles. | Sci Total Environ | 2021 | https://conductscience.org/library/papers/34247076 | PubMed |
| 13 | 34521246 | miR-210 hypoxamiR in Angiogenesis and Diabetes. | Antioxid Redox Signal | 2022 | https://conductscience.org/library/papers/34521246 | PubMed |
| 14 | 38802815 | Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study. | BMC Health Serv Res | 2024 | https://conductscience.org/library/papers/38802815 | PubMed |
| 15 | 35126450 | Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey. | Front Genet | 2021 | https://conductscience.org/library/papers/35126450 | PubMed |
| 16 | 24839362 | Hydroxyurea in sickle cell disease: drug review. | Indian J Hematol Blood Transfus | 2014 | https://conductscience.org/library/papers/24839362 | PubMed |
| 17 | 35750558 | Determinants of severity in sickle cell disease. | Blood Rev | 2022 | https://conductscience.org/library/papers/35750558 | PubMed |
| 18 | 40796944 | In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/40796944 | PubMed |
| 19 | 17482553 | An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. | Cell | 2007 | https://conductscience.org/library/papers/17482553 | PubMed |
| 20 | 36295630 | miRNA Expression Associated with HbF in Saudi Sickle Cell Anemia. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/36295630 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42014656
GET https://conductscience.org/api/papers/v1/42014656/references?page=2